SONY-DADC-BIOSCIENCES
1.3.2016 19:37:18 CET | Business Wire | Press release
MyCartis , the provider of fully integrated and broadly applicable molecular diagnostics and immunodiagnostics solutions, and Sony DADC BioSciences today announced the cooperation in the production of a microfluidic assay cartridge for MyCartis’ EvalutionTM digital multiplex analysis platform to support a range of applications in the clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic acid-based biomarkers.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160229005056/en/
Sony DADC BioSciences, a leading supplier of smart polymer parts for the biomedical industry, is using their ISO 13485-certified facility in Salzburg, Austria for manufacturing. The customized foil bonded cartridge is manufactured as a monolithic molded microtiter size plate that has optical transparency and combines macrostructures, high precision microstructures and filter structures for achieving the ultra-sensitivity of the EvalutionTM System.
“We are very pleased to be working with Sony DADC BioSciences as our development and manufacturing partner for the EvalutionTM cartridge. The collaboration between the two companies brings together a broad range of knowledge and experience, which are important for the success of innovative new technologies such as the EvalutionTM System,” said Joris Schuurmans, CEO of MyCartis.
The highly integrated assay cartridge contains reaction and detection chambers to ensure short time to result and minimal processing steps. Next to the ability to run 1 to 16 samples at the same time the EvalutionTM System further delivers superior data quality and rapid results.
“We are fascinated about MyCartis’ flexible EvalutionTM platform and enjoy our mutual team spirit. From a manufacturing perspective, the project enhances our capabilities in both injection molding and bonding of microfluidic consumables in micro titer plate format – the de facto industry standard,” said Werner Balika, Engineering Manager at Sony DADC BioSciences GmbH.
About MyCartis
MyCartis' innovative research and diagnostic system, called EvalutionTM , features the measurement and detection of molecular components of different nature (proteins, nucleic acids…), indicative of a specific pathological state in a multiplex format. The new semi-automated system is highly user-friendly thanks to its integrated workflow and provides rapid and robust results thanks to improved kinetics in the microfluidic channels. In addition, MyCartis develops ready-to-use multiplex assays with major clinical and compelling health economic values, through its own development efforts as well as through strategic partnerships. Oncology, neurology, cardiology and immunology are MyCartis' primary focus.
For more information please visit http://www.mycartis.net/
About Sony DADC BioSciences GmbH
Building on Sony DADC’s experience in high-precision optical disc manufacturing, Sony DADC BioSciences partners with Life Sciences and Diagnostics companies enabling the industrial manufacturing of smart polymer parts.
For more information please visit http://biosciences.sonydadc.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160229005056/en/
Contact:
MyCartis NV
François Topin
+32 9 241 11 60
ftopin@mycartis.net
or
Sony
DADC BioSciences GmbH
Ricarda Pichler
+43 6246 880 8142
ricarda.pichler@sonydadc.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom